Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - IOMED, Inc. (AMEX:IOX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug 28Price hit new 52-week low ($2.20)
Location
2441 South 3850 West, Suite A
Salt Lake City, UT 84120
Phone: (801) 975-1191
Fax: (801) 972-9072
Email: info@iomed.com
Employees (last reported count): 70
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 59%
·Over the last 6 months:
 · one insider buy; 10.0K shares (0.3% of insider shares)
·Institutional: 2% (5% of float)
(10 institutions)
·Net Inst. Selling: 15.0K shares (+11.91%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
IOMED, Inc. is a specialty pharmaceutical company focused on satisfying substantial unmet medical needs in large pharmaceutical markets. The Company is currently pursuing research, product development and commercialization activities in the local inflammation and ophthalmic markets. The Company is funded, in part, by an established business engaged in the manufacture and sale of iontophoretic drug delivery systems primarily used to treat acute local inflammation in the sports and occupational medicine and physical therapy markets. The Company currently markets an iontophoretic product to the physical therapy market used to deliver a potent corticosteriod. Using this product, over 13 million treatments have been clinically administered to treat inflammation. The Company is also developing products in other therapeutic areas, including ophthalmic disease and pain control.
More from Market Guide: Expanded Business Description

Financial Summary
IOX is a specialty pharmaceutical company that is pursuing research, product development, and commercialization activities in the local inflamation and opthalmic markets; it currently markets an iontophoretic product to the physical therapy market. For the nine months ended 3/31/01, revenues rose 7% to $8.4 million. Net loss totaled $4.1 million, up from $479 thousand. Results reflect growth in the IOGEL product line, offset by higher development programs costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Peter Wardle, 65
Chairman
--  
James Weersing, 61
Pres and CEO, Director
$290K
Robert Lollini, 46
Exec. VP-Fin., CFO, Sec.
205K
Steven Hamilton, 49
Exec. VP, Bus. Devel.
196K
W. Tim Miller, 49
Exec. VP, IOMED Clinical Systems
219K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:IOXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 28-Aug-2001
$2.20 
Recent Price$2.60 
52-Week High
on 6-Nov-2000
$6.813
Beta0.68 
Daily Volume (3-month avg)5,682 
Daily Volume (10-day avg)22.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-27.0%
52-Week Change
relative to S&P500
-2.1%
Share-Related Items
Market Capitalization$17.0M
Shares Outstanding6.54M
Float2.70M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.04 
Earnings (ttm)-$0.73 
Earnings (mrq)-$0.35 
Sales (ttm)$1.74 
Cash (mrq)$1.74 
Valuation Ratios
Price/Book (mrq)2.51 
Price/EarningsN/A 
Price/Sales (ttm)1.50 
Income Statements
Sales (ttm)$11.4M
EBITDA (ttm)-$5.09M
Income available to common (ttm)-$4.79M
Profitability
Profit Margin (ttm)-42.2%
Operating Margin (ttm)-50.0%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter31-Mar-2001
Management Effectiveness
Return on Assets (ttm)-24.46%
Return on Equity (ttm)-49.29%
Financial Strength
Current Ratio (mrq)6.64 
Debt/Equity (mrq)0.25 
Total Cash (mrq)$11.4M
Short Interest
As of 9-July-2001
Shares Short0 
Shares Short
(Prior Month)
0 
Daily Volume4,000 
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.